Sinclair Pharma has reported H1 2017 revenues of £ 20.1m ( $27.2m ), an increase of 16% on last year's figure of £17.3m . The growth is attributed to strong demand for Sinclair 's aesthetic dermatology products in Brazil . Sinclair also said Chris Spooner sales were up 20% to £7.3m, and first -sales for Silhouette InstaLift hit $27.2m . Chief Executive Chris Spooner said the company is confident it will deliver strong sales growth in the second half and an adjusted EBITDA profit for the year ending December 31, 2017. Even better results are expected in last year's , according to CEO Silhouette Soft .
Sinclair Pharma has reported H1 2017 revenues of £20.1m ( $27.2m ), an increase of 16% on last year's figure of £17.3m . The growth is attributed to strong demand for Sinclair 's aesthetic dermatology products in Brazil . Sinclair also said Chris Spooner sales were up 20% to £7.3m, and first -sales for Silhouette InstaLift hit $27.2m . Even better results are expected in last year's , according to CEO Silhouette Soft .